BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36477250)

  • 1. Difference in failure patterns after stereotactic body radiotherapy for lung cancer according to clinical T stage based on 4D computed tomography.
    Inagaki T; Doi H; Inada M; Ishida N; Ri A; Tatsuno S; Wada Y; Uehara T; Nakamatsu K; Hosono M; Nishimura Y
    Strahlenther Onkol; 2023 May; 199(5):465-476. PubMed ID: 36477250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
    Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
    Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer.
    Steber CR; Hughes RT; Soike MH; Helis CA; Nieto K; Jacobson T; Nagatsuka M; McGinnis HS; Leyrer CM; Farris MK
    Acta Oncol; 2021 May; 60(5):605-612. PubMed ID: 33645424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database.
    Shioyama Y; Onishi H; Takayama K; Matsuo Y; Takeda A; Yamashita H; Miyakawa A; Murakami N; Aoki M; Matsushita H; Matsumoto Y; Shibamoto Y;
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818783904. PubMed ID: 29983096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Setting up a lung stereotactic body radiotherapy service in a tertiary center in Eastern India: The process, quality assurance, and early experience.
    Shrimali RK; Saha A; Arun B; Prasath S; Nallathambi C; Bhoumik S; Mallick I; Achari RB; Chatterjee S
    J Cancer Res Ther; 2020; 16(4):888-899. PubMed ID: 32930136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
    von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
    Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.
    Verma V; Schonewolf CA; Cushman TR; Post CM; Doms A; Berman AT; DeVries M; Katz SI; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):502-510. PubMed ID: 30111509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
    Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
    PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
    Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
    Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
    Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
    Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated Nodal Failure after Stereotactic Body Radiotherapy for Lung Cancer: The Role for Salvage Mediastinal Radiotherapy.
    Ward MC; Oh SC; Pham YD; Woody NM; Marwaha G; Videtic GM; Stephans KL
    J Thorac Oncol; 2016 Sep; 11(9):1558-64. PubMed ID: 27223455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstitution of internal target volumes by combining four-dimensional computed tomography and a modified slow computed tomography scan in stereotactic body radiotherapy planning for lung cancer.
    Jang SS; Huh GJ; Park SY; Yang PS; Chung HN; Seo JH; Park JC; Yang YJ; Cho EY
    Radiat Oncol; 2014 May; 9():106. PubMed ID: 24885768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
    Kann BH; Verma V; Stahl JM; Ross R; Dosoretz AP; Shafman TD; Gross CP; Park HS; Yu JB; Decker RH
    Radiother Oncol; 2019 May; 134():44-49. PubMed ID: 31005223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.